title: MAGE-A3 expression is an adverse prognostic factor in diffuse large B-cell lymphoma.
abstract: This study evaluates the prognostic value of MAGE-A3 expression in 28 diffuse large B-cell lymphoma (DLBCL) patients. A significant association was observed between MAGE-A3 expressions, assessed by quantitative real-time RT-polymerase chain reaction (PCR), with advanced stages of disease (P < 0.05). Elevated serum lactate dehydrogenase (LDH) levels and International Prognostic Index (IPI) score were significantly higher in MAGE-A3-positive patients (P = 0.025 and P = 0.004, respectively). Expression of MAGE-A3 was associated with poor response to treatment and a significantly shorter overall survival (P < 0.001). Our data address new information in the association of MAGE-A3 expression and poor prognosis in DLBCL patients.
authors.affiliation: Laboratorio de Biología Molecular, Servicio de Hematología, Hospital General de México, México D.F., México.
authors.forename: Irma
authors.initials: I
authors.lastname: Olarte
authors.forename: Adolfo
authors.initials: A
authors.lastname: Martinez
authors.forename: Christian
authors.initials: C
authors.lastname: Ramos-Peñafiel
authors.forename: Humberto
authors.initials: H
authors.lastname: Castellanos-Sinco
authors.forename: Jorge
authors.initials: J
authors.lastname: Zamora
authors.forename: Juan
authors.initials: J
authors.lastname: Collazo-Jaloma
authors.forename: Mario
authors.initials: M
authors.lastname: Gutiérrez
authors.forename: Laila
authors.initials: L
authors.lastname: Gutiérrez-Kobeh
authors.forename: Pedro
authors.initials: P
authors.lastname: Chavez-Olmos
authors.forename: Hugo
authors.initials: H
authors.lastname: Manzanilla
authors.forename: Efraín
authors.initials: E
authors.lastname: Garrido-Guerrero
authors.forename: Rosa M
authors.initials: RM
authors.lastname: Ordoñez-Razo
authors.forename: Enrique I
authors.initials: EI
authors.lastname: Miranda
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000951:Antigens, Neoplasm / Q000235:genetics* / Q000378:metabolism; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D015153:Blotting, Western; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007770:L-Lactate Dehydrogenase / Q000097:blood; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy / Q000235:genetics* / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000235:genetics* / Q000378:metabolism; D009367:Neoplasm Staging; D011379:Prognosis; D020133:Reverse Transcriptase Polymerase Chain Reaction; D016019:Survival Analysis; D013997:Time Factors; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000951:Antigens, Neoplasm; C072013:MAGEA3 protein, human; D009363:Neoplasm Proteins; D007770:L-Lactate Dehydrogenase